Analysts Set Expectations for CRDF Q3 Earnings

Key Points

• HC Wainwright expects Cardiff Oncology to report a Q3 2026 loss of $0.13 per share and maintains a “Buy” rating. The full-year 2026 consensus estimate is a loss of $0.61 per share.
• Analyst sentiment is mixed but leans cautious: Cardiff has an average “Hold” rating, with three Buys, three Holds and one Sell, and a consensus price target of $7.50.
• Cardiff Oncology shares opened at $1.35, while the clinical-stage biotech recently reported a wider-than-expected quarterly loss of $0.14 per share. Institutional investors own 16.29% of the company, including a new $1.27 million position from BlackRock.

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - HC Wainwright issued their Q3 2026 earnings per share estimates for Cardiff Oncology in a research report issued on Tuesday, September 15th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Cardiff Oncology's Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.33) EPS.

Other research analysts have also recently issued research reports about the stock. William Blair cut shares of Cardiff Oncology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 11th. TD Cowen cut Cardiff Oncology from a "buy" rating to a "hold" rating in a report on Monday, June 1st. Weiss Ratings raised Cardiff Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, September 4th. Wall Street Zen upgraded Cardiff Oncology from a "strong sell" rating to a "sell" rating in a research report on Saturday, September 5th. Finally, Craig Hallum cut Cardiff Oncology from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a research report on Wednesday, June 3rd. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Cardiff Oncology has an average rating of "Hold" and a consensus target price of $7.50.

Cardiff Oncology Stock Up 0.7%

Shares of NASDAQ:CRDF opened at $1.35 on Thursday. The company has a market cap of $105.02 million, a PE ratio of -2.25 and a beta of 1.46. The company's 50-day moving average price is $1.01 and its 200 day moving average price is $1.41. Cardiff Oncology has a fifty-two week low of $0.76 and a fifty-two week high of $3.31.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.06 million.

Institutional Trading of Cardiff Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in CRDF. BlackRock Inc. bought a new stake in Cardiff Oncology during the second quarter worth approximately $1,265,000. Glenview Trust Co bought a new position in Cardiff Oncology during the 2nd quarter valued at $56,000. Capstone Investment Advisors LLC bought a new position in Cardiff Oncology during the 2nd quarter valued at $67,000. Hsbc Holdings PLC acquired a new position in shares of Cardiff Oncology during the 2nd quarter valued at $37,000. Finally, Ieq Capital LLC acquired a new position in shares of Cardiff Oncology during the 2nd quarter valued at $58,000. 16.29% of the stock is currently owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company's lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.